Scarica l'app Stockscreener
9.80
0.72%
0.07
Dopo l'orario di chiusura:
9.80
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché FOLD Giù?
Forum
Previsione
Amicus Therapeutics Inc Borsa (FOLD) Ultime notizie
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Fabry Disease Treatment Market Growth in Future Scope 2024-2031 - openPR
FOLD: 3 High-Growth Biotech Stocks to Watch - StockNews.com
Amicus Therapeutics (NASDAQ:FOLD) Rating Lowered to "Hold" at StockNews.com - MarketBeat
Y Intercept Hong Kong Ltd Has $374,000 Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Shares Up 5.2%Time to Buy? - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock Position Lessened by Orion Portfolio Solutions LLC - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Shares Gap Down – Here’s What Happened - Defense World
Amicus Therapeutics (NASDAQ:FOLD) Shares Gap DownTime to Sell? - MarketBeat
Morgan Stanley upgrades PTC, cuts Immuneering, Amicus (PTCT:NASDAQ) - Seeking Alpha
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday? - Yahoo Finance
Amicus Therapeutics (FOLD) is a Top-Ranked Momentum Stock: Should You Buy? - MSN
Morgan Stanley cuts Amicus Therapeutics shares to Equalweight rating By Investing.com - Investing.com UK
Amicus Therapeutics' (FOLD) Equal Weight Rating Reaffirmed at Morgan Stanley - MarketBeat
Neo Ivy Capital Management Takes Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 47,310 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Fmr LLC Decreases Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Old West Investment Management LLC Increases Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Upgraded to Buy at StockNews.com - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stake Raised by Wellington Management Group LLP - MarketBeat
Point72 Asset Management L.P. Makes New $13.53 Million Investment in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Why Is Amicus Therapeutics (FOLD) Down 11.1% Since Last Earnings Report? - Yahoo Finance
Point72 DIFC Ltd Invests $704,000 in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Janus Henderson Group PLC Trims Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Acquired by Charles Schwab Investment Management Inc. - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock Holdings Cut by Redmile Group LLC - MarketBeat
Parkman Healthcare Partners LLC Has $6.47 Million Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Erste Asset Management GmbH Makes New $1.25 Million Investment in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
BNP Paribas Financial Markets Purchases 225,222 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics CEO Campbell Bradley sells $75,124 in stock - Investing.com India
Amicus Therapeutics CEO Campbell Bradley sells $75,124 in stock By Investing.com - Investing.com UK
Pompe Disease Market is expected to rise at a Significant CAGR, DelveInsight | Pompe Disease Therapies, Clinical trials, Treatment Options, Companies | Genzyme, Sanofi, Amicus Therapeutics, Actus - The Globe and Mail
Pompe Disease Market is expected to rise at a Significant CAGR, - openPR
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock Position Boosted by Edgestream Partners L.P. - MarketBeat
PDT Partners LLC Buys New Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Intech Investment Management LLC Takes $834,000 Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Algert Global LLC Purchases 170,575 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Massachusetts Financial Services Co. MA Has $33.75 Million Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Increases Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Principal Financial Group Inc. Lowers Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
(FOLD) Technical Data - Stock Traders Daily
Here's What Key Metrics Tell Us About Amicus Therapeutics (FOLD) Q3 Earnings - MSN
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Victory Capital Management Inc. - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Rating Increased to Buy at StockNews.com - MarketBeat
Redmile Group, LLC Increases Stake in Amicus Therapeutics Inc - GuruFocus.com
Protein Therapeutics Market Size to be Worth USD 549.4 billion by 2031, at a CAGR of 6.3% | Transparency Market Research, Inc. - GlobeNewswire Inc.
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC Acquires Shares in Amic - GuruFocus.com
Amicus' Q3 Earnings & Revenues Beat Estimates, '24 View Updated - MSN
Avoro Capital Advisors LLC Adjusts Stake in Amicus Therapeutics Inc - GuruFocus.com
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Purchased by GSA Capital Partners LLP - MarketBeat
A Closer Look at 8 Analyst Recommendations For Amicus Therapeutics - Benzinga
The Analyst Verdict: Amicus Therapeutics In The Eyes Of 8 Experts - Benzinga
Amicus Therapeutics Stock: A Deep Dive Into Analyst Perspectives (8 Ratings) - Benzinga
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):